Leadership Shuffles at AstraZeneca, Janssen China, and GSK Amid Strategic Realignment

Feb 28, 2024 17:30 CST Updated 17:30

GSK

Pharmaceutical R&D Manufacturer

AstraZeneca

Biopharmaceutical Manufacturer

Johnson & Johnson Innovative Medicine

Pharmaceutical R&D Developer

According to the "Pharmaceutical Representative" news, recently, AstraZeneca, Johnson & Johnson Innovative Medicine, and GlaxoSmithKline, three multinational pharmaceutical companies, have all experienced personnel changes.

AstraZeneca China Appoints Head of NPP Team

AstraZeneca China appoints Sun Shuang as the head of the NPP (New Product Planning) team for the Respiratory Nebulization, Digestive, Vaccines and Immunotherapy, and Autoimmune divisions.

Sun Shuang graduated from the Pharmacy program at Peking University, later pursued graduate studies at Peking University, and obtained a Ph.D. in Chemical Biology from the University of Cambridge. Before joining AstraZeneca, Sun Shuang served as the Project Manager for the healthcare industry at Boston Consulting Group (BCG) and also worked as an internal consultant at Merck.

Johnson & Johnson Innovative Medicine China's Solid Tumor Business Unit Leader Appointed, Coming from Novartis

On February 26, Wang Wei officially joined Johnson & Johnson Innovative Medicine (formerly Janssen) China Oncology Business Unit as the Head of the Solid Tumor Business Unit, taking full responsibility for the business decisions and management of Johnson & Johnson Innovative Medicine’s China Solid Tumor Business Unit. Liu Ao, the leader of the solid tumor marketing team, along with the managers of the five regions of the sales team, will report directly to Wang Wei.

Previously, Wang Wei worked at Xi'an Janssen for many years, holding positions such as Brand Manager and Senior Marketing Manager of the Central Nervous System Pipeline in the Strategic Marketing Department. He joined Novartis in 2015, serving successively as the Brand Head of the Hematology Marketing Department at Novartis Oncology (China), Head of the Regional Marketing Department, and Head of the North Region One of the Hematology Business Unit at Novartis Oncology China. His last position at Novartis was the Head of the Hematology Oncology Field for Novartis Innovative Medicines China.

GSK Replaces Compliance Head in China

On February 27, GSK China announced that Tingting Zhai, the current Core Business, Anti-Infectives and R&D Finance Director, will assume the role of China Compliance Head. She will report directly to Christine Ng, Vice President of GSK and GCI Compliance Officer, and join the GSK China Leadership Team.

GSK's current China Compliance Head, Zhang Xuhao, will complete his term in July this year. The handover of duties will begin next month, and the subsequent appointment has not been announced yet.

Zhai Tingting holds a master's degree in accounting and an MBA from Duke University. She has worked in the Investment Banking Department of HSBC Hong Kong and the Strategy Development Department of China Merchants Group International. Later, she joined Eli Lilly as a finance professional and internal consultant. In 2014, Zhai Tingting joined the finance department of GSK, successively serving as the Finance Director for Prescription Drugs and Vaccines, Finance Director for the Prescription Drug Supply Chain, and Finance Director for R&D.

Source: Medical Representative

Compiled by: Nicole

ClickRead the Original Text Learn More